FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan
| Autor: | Satoshi Kobayashi, Masato Ozaka, Shuhei Suzuki, Ippei Matsumoto, Akiko Todaka, Katsuhiro Omae, Hideki Ueno, Kazuhiro Uesugi, Keiko Kamei, Hidehiko Matsuoka, Akira Fukutomi, Marina Kobayashi, Nobumasa Mizuno |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Subset Analysis
Oncology Adult Male medicine.medical_specialty FOLFIRINOX Endocrinology Diabetes and Metabolism Leucovorin Antineoplastic Agents Neutropenia Adenocarcinoma Irinotecan 03 medical and health sciences 0302 clinical medicine Japan Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Adverse effect Aged Hepatology business.industry Gastroenterology Middle Aged medicine.disease Prognosis Clinical trial Oxaliplatin Pancreatic Neoplasms Tolerability 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Female Fluorouracil business Febrile neutropenia medicine.drug |
| Zdroj: | Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. 19(2) |
| ISSN: | 1424-3911 0000-1465 |
| Popis: | Background FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, leucovorin) treatment significantly improved overall survival in the recent phase III study and became a standard therapy for metastatic pancreatic cancer. However, treatment for locally advanced pancreatic cancer is still controversial. We conducted subset analyses from a nation-wide multicenter observational study in Japan to evaluate the tolerability and efficacy of FOLFIRINOX in patients with locally advanced pancreatic cancer and to investigate independent prognostic factors with pre-treatment variables. Methods The study included 66 patients with unresectable locally advanced pancreatic cancer from 27 institutions in Japan who received FOLFIRINOX as first-line treatment between December 20, 2013 and December 19, 2014 and surveyed until December 2015. Results The median age was 63 with the Eastern Cooperative Oncology Group performance status of 0 or 1. Major Grade 3 or 4 adverse events included neutropenia (64%), leukopenia (33%), febrile neutropenia (15%), and diarrhea (15%). Severe adverse event occurred in 14 patients (11%) without fatal event. The median overall survival and progression-free survival times were 18.5 and 7.6 months, respectively. The objective response rate 15.2% and the disease control rate was 81.9%. A high modified Glasgow prognostic score (mGPS, ≥1) (95%CI 1.96–12.5) and female (95%CI 0.20–0.97) were identified as independent poor prognostic factors. Conclusions First-line FOLFIRINOX treatment for locally advanced pancreatic cancer seems to be effective with acceptable toxicities. A high mGPS may be associated with poor survival in patients with locally advanced pancreatic cancer who receive FOLFIRINOX. This study was registered at the UMIN Clinical Trials Registry (UMIN000014658). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect